Investigational Drug Details
| Drug ID: | D309 |
| Drug Name: | Irbesartan |
| Synonyms: | |
| Type: | small molecule |
| DrugBank ID: | DB01029 |
| DrugBank Description: | Irbesartan is an angiotensin receptor blocker (ARB) indicated to treat hypertension or diabetic nephropathy.[L7456,L7459] It can also be used as part of a combination product with [hydrochlorothiazide] for patients not well controlled or not expected to be well controlled on monotherapy.[L7459] Unlike angiotensin converting enzyme inhibitors, ARBs are not associated with a dry cough.[L7456,L7459] Irbesartan was granted FDA approval on 30 September 1997.[L7456,L7459] |
| PubChem ID: | 3749 |
| CasNo: | 138402-11-6 |
| Repositioning for NAFLD: | Yes |
| SMILES: | CCCCC1=NC2(CCCC2)C(=O)N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1 |
| Structure: |
|
| InChiKey: | YOSHYTLCDANDAN-UHFFFAOYSA-N |
| Molecular Weight: | 428.5294 |
| DrugBank Targets: | Type-1 angiotensin II receptor; Transcription factor AP-1 |
| DrugBank MoA: | Irbesartan prevents angiotensin II binding to the AT<sub>1</sub> receptor in tissues like vascular smooth muscle and the adrenal gland.[L7456,L7459] Irbesartan and its active metabolite bind the AT<sub>1</sub> receptor with 8500 times more affinity than they bind to the AT<sub>2</sub> receptor.[L7456,L7459] Irbesartan's prevention of angiotensin II binding causes vascular smooth muscle relaxation and prevents the secretion of aldosterone, lowering blood pressure.[L7456,L7459] Angiotensin II would otherwise bind to the AT<sub>1</sub> receptor, inducing vasoconstriction and aldosterone secretion, raising blood pressure.[L7456,L7459] |
| DrugBank Pharmacology: | Irbesartan is an angiotensin receptor blocker used to treat hypertension and diabetic nephropathy.[L7456,L7459] It has a long duration of action as it is usually taken once daily and a wide therapeutic index as doses may be as low as 150mg daily but doses of 900mg/day were well tolerated in healthy human subjects.[L7456,L7459,A181165] |
| DrugBank Indication: | Irbesartan is indicated to treat hypertension and diabetic nephropathy in hypertensive patients with type 2 diabetes, elevated serum creatinine, and proteinuria.[L7456] A combination product with hydrochlorothiazide is indicated for hypertension in patients with uncontrolled hypertension with monotherapy or first line in patients not expected to be well controlled with monotherapy.[L7459] |
| Targets: | |
| Therapeutic Category: | |
| Clinical Trial Progress: | |
| Latest Progress: |
| Trial ID | Source ID | Phases | Status | Study Results | Start Date | Last Update Posted | |
|---|---|---|---|---|---|---|---|
| L0035 | NCT04990427 | PHASE1 | COMPLETED | NO | 2022-01-10 | 2024-10-09 | Details |
| L0749 | NCT02440581 | COMPLETED | YES | 2015-07-01 | 2023-01-05 | Details | |
| L0791 | NCT04523727 | PHASE3 | RECRUITING | NO | 2022-06-16 | 2025-04-16 | Details |
| L1976 | NCT01121276 | PHASE1 | COMPLETED | NO | 2010-04 | 2017-01-18 | Details |
| L2234 | NCT00535925 | PHASE4 | COMPLETED | YES | 2005-10 | 2020-08-03 | Details |
| L5500 | NCT02960659 | PHASE1|PHASE2 | COMPLETED | YES | 2017-05-09 | 2023-08-01 | Details |
| L6632 | NCT01706211 | PHASE3 | COMPLETED | NO | 1998-10 | 2012-10-15 | Details |
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Article ID | PMID | Source | Title |
|---|